Skip to main content

Compare Stocks

Date Range: 

 CelsionLumos PharmaAcasti PharmaRockwell MedicalVascular Biogenics
SymbolNASDAQ:CLSNNASDAQ:LUMONASDAQ:ACSTNASDAQ:RMTINASDAQ:VBLT
Price Information
Current Price$1.04$9.89$0.44$0.92$1.98
52 Week RangeHoldBuyHoldBuyBuy
MarketRank™
Overall Score1.31.71.21.31.3
Analysis Score3.03.53.23.53.5
Community Score2.73.32.72.42.4
Dividend Score0.00.00.00.00.0
Ownership Score0.00.80.00.00.0
Earnings & Valuation Score0.60.60.00.60.6
Analyst Ratings
Consensus RecommendationHoldBuyHoldBuyBuy
Consensus Price Target$4.00$33.50$2.98$5.50$4.67
% Upside from Price Target284.62% upside238.73% upside582.34% upside501.09% upside135.69% upside
Trade Information
Market Cap$90.02 million$82.53 million$90.85 million$85.63 million$95.41 million
Beta2.421.692.451.111.17
Average Volume14,149,29853,47532,321,5471,937,791917,883
Sales & Book Value
Annual Revenue$500,000.00$940,000.00N/A$61.30 million$560,000.00
Price / Sales180.0487.80N/A1.40170.38
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.63 per share$19.03 per share$0.14 per share$0.32 per share$1.00 per share
Price / Book1.650.52N/A2.861.98
Profitability
Net Income$-16,850,000.00$-42,990,000.00$-25,510,000.00$-34,130,000.00$-19,460,000.00
EPS($0.91)($9.27)($0.23)($0.56)($0.54)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-4,315.00%-2,053.30%N/A-47.23%-2,692.41%
Return on Equity (ROE)-104.32%-10.58%-342.52%-117.67%-61.77%
Return on Assets (ROA)-47.65%-7.83%-112.03%-46.33%-47.23%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.25%N/AN/A0.50%N/A
Current Ratio3.67%19.41%3.66%6.13%5.16%
Quick Ratio3.67%19.40%3.66%5.83%5.16%
Ownership Information
Institutional Ownership Percentage13.73%43.79%1.12%26.72%4.50%
Insider Ownership Percentage20.49%15.90%N/A4.70%N/A
Miscellaneous
Employees27283230038
Shares Outstanding86.56 million8.35 million208.38 million93.59 million48.19 million
Next Earnings Date8/13/2021 (Estimated)8/12/2021 (Estimated)7/5/2021 (Estimated)5/17/2021 (Confirmed)8/12/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableOptionableOptionable
SourceHeadline
What Is The Ownership Structure Like For Vascular Biogenics Ltd. (NASDAQ:VBLT)?What Is The Ownership Structure Like For Vascular Biogenics Ltd. (NASDAQ:VBLT)?
nasdaq.com - May 14 at 12:47 AM
$300,000.00 in Sales Expected for Vascular Biogenics Ltd. (NASDAQ:VBLT) This Quarter$300,000.00 in Sales Expected for Vascular Biogenics Ltd. (NASDAQ:VBLT) This Quarter
americanbankingnews.com - May 13 at 2:34 AM
Vascular Biogenics (NASDAQ:VBLT) Posts Quarterly  Earnings Results, Beats Expectations By $0.01 EPSVascular Biogenics (NASDAQ:VBLT) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS
americanbankingnews.com - May 12 at 12:10 PM
Vascular Biogenics Ltd. (NASDAQ:VBLT) Expected to Announce Earnings of -$0.13 Per ShareVascular Biogenics Ltd. (NASDAQ:VBLT) Expected to Announce Earnings of -$0.13 Per Share
americanbankingnews.com - May 11 at 5:18 PM
Vascular Biogenics (VBLT) Reports Q1 Loss, Lags Revenue EstimatesVascular Biogenics (VBLT) Reports Q1 Loss, Lags Revenue Estimates
finance.yahoo.com - May 11 at 1:19 PM
Vascular Biogenics: Q1 Earnings SnapshotVascular Biogenics: Q1 Earnings Snapshot
houstonchronicle.com - May 11 at 8:18 AM
VBL Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate UpdateVBL Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
finance.yahoo.com - May 11 at 8:18 AM
Vascular Biogenicss Earnings: A PreviewVascular Biogenics's Earnings: A Preview
benzinga.com - May 10 at 12:16 PM
Vascular Biogenics (VBLT) to Release Earnings on TuesdayVascular Biogenics (VBLT) to Release Earnings on Tuesday
americanbankingnews.com - May 5 at 11:13 AM
VBL Therapeutics to Report First Quarter Financial Results on May 11VBL Therapeutics to Report First Quarter Financial Results on May 11
finance.yahoo.com - May 4 at 7:39 AM
Vascular Biogenics Ltd. [VBLT] is 19.58% higher this YTD. Is it still time to buy?Vascular Biogenics Ltd. [VBLT] is 19.58% higher this YTD. Is it still time to buy?
dbtnews.com - May 3 at 10:08 AM
Vascular Biogenics Ltd (VBLT)Vascular Biogenics Ltd (VBLT)
investing.com - April 30 at 1:48 PM
Vascular Biogenics Ltd. (NASDAQ:VBLT)Metrics You Need to Know Right NowVascular Biogenics Ltd. (NASDAQ:VBLT)Metrics You Need to Know Right Now
stocksregister.com - April 29 at 12:36 PM
Vascular Biogenics Ltd. [VBLT] gain 13.76% so far this year. What now?Vascular Biogenics Ltd. [VBLT] gain 13.76% so far this year. What now?
dbtnews.com - April 29 at 12:36 PM
Vascular Biogenics Ltd. (NASDAQ:VBLT) – Analysts See The Stock Differently TodayVascular Biogenics Ltd. (NASDAQ:VBLT) – Analysts See The Stock Differently Today
marketingsentinel.com - April 28 at 3:37 PM
Zacks: Analysts Anticipate Vascular Biogenics Ltd. (NASDAQ:VBLT) Will Post Quarterly Sales of $200,000.00Zacks: Analysts Anticipate Vascular Biogenics Ltd. (NASDAQ:VBLT) Will Post Quarterly Sales of $200,000.00
americanbankingnews.com - April 26 at 5:59 AM
Vascular Biogenics Ltd. (NASDAQ:VBLT) Has Recovered 40.12% So Far, But Another 87.57% Gain Cannot Be Ruled OutVascular Biogenics Ltd. (NASDAQ:VBLT) Has Recovered 40.12% So Far, But Another 87.57% Gain Cannot Be Ruled Out
marketingsentinel.com - April 18 at 9:06 AM
Vascular Biogenics Ltd. Closes Public Offering of Ordinary Shares and Pre-Funded WarrantsVascular Biogenics Ltd. Closes Public Offering of Ordinary Shares and Pre-Funded Warrants
finance.yahoo.com - April 14 at 8:51 AM
Vascular Biogenics Ltd. (NASDAQ:VBLT) surprises Wall Street with 10.98% stock price gainVascular Biogenics Ltd. (NASDAQ:VBLT) surprises Wall Street with 10.98% stock price gain
marketingsentinel.com - April 13 at 12:43 PM
Vascular Biogenics Ltd. [VBLT] Stock trading around $1.73 per share: What’s Next?Vascular Biogenics Ltd. [VBLT] Stock trading around $1.73 per share: What’s Next?
dbtnews.com - April 12 at 2:52 PM
Does Vascular Biogenics Ltd. (NASDAQ:VBLT) Still Need To Convince Analysts?Does Vascular Biogenics Ltd. (NASDAQ:VBLT) Still Need To Convince Analysts?
stocksregister.com - April 12 at 9:32 AM
Vascular Biogenics Ltd. Prices Public Offering of Ordinary Shares and Pre-Funded WarrantsVascular Biogenics Ltd. Prices Public Offering of Ordinary Shares and Pre-Funded Warrants
finance.yahoo.com - April 9 at 1:21 PM
Vascular Biogenics Ltd. Announces Proposed Public Offering of Ordinary Shares and Pre-Funded ...Vascular Biogenics Ltd. Announces Proposed Public Offering of Ordinary Shares and Pre-Funded ...
apnews.com - April 8 at 5:55 PM
Vascular Biogenics Ltd. Announces Proposed Public Offering of Ordinary Shares and Pre-Funded WarrantsVascular Biogenics Ltd. Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
finance.yahoo.com - April 8 at 5:55 PM
VBL Therapeutics to Host Virtual R&D Day on April 6VBL Therapeutics to Host Virtual R&D Day on April 6
finance.yahoo.com - March 30 at 7:54 AM
DateCompanyBrokerageAction
7/16/2020CelsionOppenheimerDowngrade
7/13/2020CelsionDawson JamesDowngrade
7/25/2019CelsionBrookline Capital ManagementReiterated Rating
4/13/2021Lumos PharmaJonestradingInitiated Coverage
3/17/2021Lumos PharmaStifel NicolausUpgrade
12/2/2020Lumos PharmaCantor FitzgeraldInitiated Coverage
11/23/2020Lumos PharmaHC WainwrightBoost Price Target
8/25/2020Lumos PharmaPiper SandlerInitiated Coverage
8/17/2020Lumos PharmaRoth CapitalReiterated Rating
4/16/2020Lumos PharmaJefferies Financial GroupInitiated Coverage
9/2/2020Acasti PharmaAegisDowngrade
9/1/2020Acasti PharmaB. RileyLower Price Target
6/30/2020Acasti PharmaEchelon Wealth PartnersReiterated Rating
7/18/2019Acasti PharmaCIBCInitiated Coverage
11/11/2019Rockwell MedicalPiper Jaffray CompaniesLower Price Target
6/19/2019Rockwell MedicalIfs SecuritiesDowngrade
12/10/2020Vascular BiogenicsChardan CapitalReiterated Rating
(Data available from 5/15/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.